Immunomedics, Inc. (IMMU) Develops Novel Dual System for Tumor Detection and Imaging
6/10/2013 9:19:38 AM
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
VANCOUVER, British Columbia, June 10, 2013 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (Nasdaq:IMMU), a biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases, today announced the development of a pretargeting system that can detect and optically image a tumor during surgery. Results from this preclinical study were presented by Dr. Mark Rijpkema of the Department of Nuclear Medicine, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands.
Help employers find you! Check out all the jobs and post your resume.
comments powered by